ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CGIX Cancer Genetics Inc

4.61
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cancer Genetics Inc NASDAQ:CGIX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.61 4.56 4.63 0 01:00:00

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

15/05/2023 1:01pm

Edgar (US Regulatory)


 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 15

 

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File No. 001-35817

 

 

 

Vyant Bio, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

2 Executive Campus

2370 State Route 70, Suite 310

Cherry Hill, NJ 08002

(201) 479-1357

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock, par value $0.0001 per share

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

 

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)
Rule 12g-4(a)(2)
Rule 12h-3(b)(1)(i)
Rule 12h-3(b)(1)(ii)
Rule 15d-6
Rule 15d-22(b)

 

Approximate number of holders of record as of the certification or notice date: 71

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Vyant Bio, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

 

 

 
 

 

  VYANT BIO, INC.
   
  By: /s/ Andrew D. C. LaFrence
  Name: Andrew D. C. LaFrence
  Title: President, Chief Executive Officer and Chief Financial Officer
     
Date: May 15, 2023    

 

 

 

1 Year Cancer Genetics Chart

1 Year Cancer Genetics Chart

1 Month Cancer Genetics Chart

1 Month Cancer Genetics Chart

Your Recent History

Delayed Upgrade Clock